These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38426611)

  • 1. Serum PRO-C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort.
    Tang LJ; Sun DQ; Song SJ; Yip TC; Wong GL; Zhu PW; Chen SD; Karsdal M; Leeming DJ; Jiang P; Wang C; Chen Q; Byrne CD; Targher G; Eslam M; George J; Wong VW; Zheng MH
    Liver Int; 2024 May; 44(5):1129-1141. PubMed ID: 38426611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD.
    Tang LJ; Li G; Eslam M; Zhu PW; Chen SD; Leung HH; Huang OY; Wong GL; Zhou YJ; Karsdal M; Leeming DJ; Jiang P; Wang C; Yuan HY; Byrne CD; Targher G; George J; Wong VW; Zheng MH
    Hepatol Int; 2023 Feb; 17(1):190-201. PubMed ID: 36152131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD.
    Tang LJ; Ma HL; Eslam M; Wong GL; Zhu PW; Chen SD; Leeming DJ; Karsdal M; Li G; Huang OY; Leung HH; Zhou YJ; Feng Q; Jiang P; Gao LM; Byrne CD; Targher G; George J; Wong VW; Zheng MH
    Metabolism; 2022 Mar; 128():154958. PubMed ID: 34958817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ADAPT: An Algorithm Incorporating PRO-C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis.
    Daniels SJ; Leeming DJ; Eslam M; Hashem AM; Nielsen MJ; Krag A; Karsdal MA; Grove JI; Neil Guha I; Kawaguchi T; Torimura T; McLeod D; Akiba J; Kaye P; de Boer B; Aithal GP; Adams LA; George J
    Hepatology; 2019 Mar; 69(3):1075-1086. PubMed ID: 30014517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRO-C3, liver fibrosis and CKD: The plot thickens.
    Lonardo A
    Liver Int; 2024 May; 44(5):1126-1128. PubMed ID: 38634694
    [No Abstract]   [Full Text] [Related]  

  • 6. Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence.
    Gao J; Li Y; Zhang Y; Zhan X; Tian X; Li J; Wang R; He Y; Wang A; Wu S
    J Am Heart Assoc; 2024 Mar; 13(5):e032604. PubMed ID: 38390843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MAFLD and risk of CKD.
    Sun DQ; Jin Y; Wang TY; Zheng KI; Rios RS; Zhang HY; Targher G; Byrne CD; Yuan WJ; Zheng MH
    Metabolism; 2021 Feb; 115():154433. PubMed ID: 33212070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of metabolic dysfunction-associated fatty liver disease with chronic kidney disease: a Chinese population-based study.
    Hu Q; Chen Y; Bao T; Huang Y
    Ren Fail; 2022 Dec; 44(1):1996-2005. PubMed ID: 36374233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease.
    Pan Z; Derbala M; AlNaamani K; Ghazinian H; Fan JG; Eslam M
    Ann Hepatol; 2024; 29(5):101512. PubMed ID: 38710473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Metabolic Dysfunction-Associated Fatty Liver Disease in Developing Chronic Kidney Disease: Longitudinal Cohort Study.
    Wei S; Song J; Xie Y; Huang J; Yang J
    JMIR Public Health Surveill; 2023 May; 9():e45050. PubMed ID: 37140958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Sequential Algorithm Combining ADAPT and Liver Stiffness Can Stage Metabolic-Associated Fatty Liver Disease in Hospital-Based and Primary Care Patients.
    Eslam M; Wong GL; Hashem AM; Chan HL; Nielsen MJ; Leeming DJ; Chan AW; Chen Y; Duffin KL; Karsdal M; Schattenberg JM; George J; Wong VW
    Am J Gastroenterol; 2021 May; 116(5):984-993. PubMed ID: 33252454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-invasive prediction nomogram for predicting significant fibrosis in patients with metabolic-associated fatty liver disease: a cross-sectional study.
    Zhang F; Han Y; Mao Y; Zheng G; Liu L; Li W
    Ann Med; 2024 Dec; 56(1):2337739. PubMed ID: 38574396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population.
    Nielsen MJ; Leeming DJ; Goodman Z; Friedman S; Frederiksen P; Rasmussen DGK; Vig P; Seyedkazemi S; Fischer L; Torstenson R; Karsdal MA; Lefebvre E; Sanyal AJ; Ratziu V
    J Hepatol; 2021 Dec; 75(6):1292-1300. PubMed ID: 34454994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of transient elastography in diagnosing MAFLD and the early effects of sleeve gastrectomy on MAFLD among the Chinese population.
    Hu R; Wu B; Wang C; Wu Z; Zhang X; Chen X; Lu G; Yuan K
    Int J Surg; 2024 Apr; 110(4):2044-2054. PubMed ID: 38215263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations between metabolic dysfunction-associated fatty liver disease, chronic kidney disease, and abdominal obesity: a national retrospective cohort study.
    Cen C; Fan Z; Ding X; Tu X; Liu Y
    Sci Rep; 2024 Jun; 14(1):12645. PubMed ID: 38825630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of metabolic dysfunction-associated fatty liver disease, type 2 diabetes mellitus, and metabolic goal achievement with risk of chronic kidney disease.
    Su W; Chen M; Xiao L; Du S; Xue L; Feng R; Ye W
    Front Public Health; 2022; 10():1047794. PubMed ID: 36420005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: A systematic review and meta-analysis.
    Agustanti N; Soetedjo NNM; Damara FA; Iryaningrum MR; Permana H; Bestari MB; Supriyadi R
    Diabetes Metab Syndr; 2023 May; 17(5):102780. PubMed ID: 37201293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coexistence of Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Kidney Disease Is a More Potent Risk Factor for Ischemic Heart Disease.
    Miyamori D; Tanaka M; Sato T; Endo K; Mori K; Mikami T; Hosaka I; Hanawa N; Ohnishi H; Furuhashi M
    J Am Heart Assoc; 2023 Jul; 12(14):e030269. PubMed ID: 37421273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MAFLD fibrosis score: Using routine measures to identify advanced fibrosis in metabolic-associated fatty liver disease.
    Cheung JTK; Zhang X; Wong GL; Yip TC; Lin H; Li G; Leung HH; Lai JC; Mahadeva S; Nik Mustapha NR; Wang XD; Liu WY; Wong VW; Chan WK; Zheng MH
    Aliment Pharmacol Ther; 2023 Dec; 58(11-12):1194-1204. PubMed ID: 37724633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Stroke With Metabolic Dysfunction-Associated Fatty Liver Disease With and Without CKD.
    Li Y; Wu S; Gao J; Zhang Y; Zuo Y; Tian X; Chen S; Xing A; Wang A; He Y
    Am J Kidney Dis; 2024 Apr; 83(4):477-488. PubMed ID: 37838141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.